{"id":"half-dose-cbd","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Drowsiness"},{"rate":"5-15%","effect":"Dry mouth"}]},"_chembl":{"chemblId":"CHEMBL6039930","moleculeType":null,"molecularWeight":"314.47"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By reducing the dose, it aims to minimize side effects while still engaging with cannabinoid receptors CB1 and CB2, which can influence pain, inflammation, and other functions.","oneSentence":"Half dose CBD is a reduced form of cannabidiol that interacts with the endocannabinoid system to modulate various physiological processes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:40:36.440Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain management"},{"name":"Anxiety disorders"}]},"trialDetails":[{"nctId":"NCT07148206","phase":"PHASE3","title":"Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":40},{"nctId":"NCT05860699","phase":"PHASE2","title":"Cannabidiol as an add-on Treatment During Inpatient Alcohol Cessation : CBD-OH","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-04-08","conditions":"Severe Alcohol Use Disorder (DSM 5)","enrollment":210},{"nctId":"NCT06686914","phase":"PHASE1","title":"The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex","status":"RECRUITING","sponsor":"West Virginia University","startDate":"2025-06-30","conditions":"Cannabidiol Effects, Driving Performance","enrollment":300},{"nctId":"NCT05269628","phase":"PHASE2","title":"Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype","status":"RECRUITING","sponsor":"Tiffany J. Braley, MD, MS","startDate":"2022-03-25","conditions":"Multiple Sclerosis, Sleep, Pain","enrollment":166},{"nctId":"NCT06523725","phase":"PHASE2","title":"Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy","status":"WITHDRAWN","sponsor":"Dr. Paul Lyons","startDate":"2024-11-01","conditions":"Post-traumatic Epilepsy","enrollment":""},{"nctId":"NCT04997616","phase":"EARLY_PHASE1","title":"Determination of Cannabinoid and Cannabinoid Metabolite Levels in Healthy Volunteers","status":"WITHDRAWN","sponsor":"University of Arkansas","startDate":"2023-01-03","conditions":"Healthy","enrollment":""},{"nctId":"NCT02224690","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2015-04-28","conditions":"Epilepsy, Lennox-Gastaut Syndrome","enrollment":171},{"nctId":"NCT02091206","phase":"PHASE2","title":"A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2014-10-22","conditions":"Epilepsy, Dravet Syndrome","enrollment":34},{"nctId":"NCT02091375","phase":"PHASE3","title":"Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2015-03-30","conditions":"Epilepsy, Dravet Syndrome","enrollment":120},{"nctId":"NCT02224703","phase":"PHASE3","title":"GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2015-04-13","conditions":"Epilepsy, Dravet Syndrome","enrollment":199},{"nctId":"NCT02224560","phase":"PHASE3","title":"Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2015-06-08","conditions":"Epilepsy, Lennox Gastaut Syndrome","enrollment":225},{"nctId":"NCT01180374","phase":"EARLY_PHASE1","title":"The Effects of Cannabidiol and ∆-9-THC in Humans","status":"COMPLETED","sponsor":"Yale University","startDate":"2010-02-01","conditions":"Healthy","enrollment":27},{"nctId":"NCT01568047","phase":"PHASE2","title":"Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2010-02","conditions":"Parkinson's Disease","enrollment":40},{"nctId":"NCT02312232","phase":"PHASE1","title":"Pharmacokinetic Study in Healthy Males","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2014-11","conditions":"Parkinson's Disease","enrollment":20},{"nctId":"NCT01568034","phase":"PHASE2","title":"A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2009-04","conditions":"Parkinson's Disease","enrollment":10},{"nctId":"NCT00391898","phase":"PHASE4","title":"Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-10","conditions":"Parkinson's Disease","enrollment":95}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Active half-dose for 11 days during inpatient alcohol cessation"],"phase":"phase_2","status":"active","brandName":"Half dose CBD","genericName":"Half dose CBD","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Half dose CBD is a reduced form of cannabidiol that interacts with the endocannabinoid system to modulate various physiological processes. Used for Chronic pain management, Anxiety disorders.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}